CTLA4 and non-small cell lung carcinoma: A registered method of immunotherapy for NSCLC patients is also the combination of two ICIs: anti-PD1 (nivolumab) and anti-CTLA-4 (cytotoxic T lymphocytes antigen 4; ipilimumab) with chemotherapy.